Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rajiv Ananthakrishna has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of the Left Ventricular Myocardium in Systemic Sclerosis

    by Briella K. Egberts, Rajiv Ananthakrishna, Ranjit Shah, Antony Chun Fai So, Jennifer Walker, Sivabaskari Pasupathy, Susanna Proudman, Joseph B. Selvanayagam

    Background/Objectives: Cardiac involvement in systemic sclerosis (SSc) ranges from subclinical to severe. While pulmonary artery hypertension (PAH) is well-documented, the mechanism of left ventricular (LV) ischemia remains unclear. Oxygen-sensitive cardiovascular magnetic resonance (OS-CMR) imaging offers a novel approach to assessing myocardial oxygenation and ischemia. This study evaluated the changes in myocardial deoxygenation in response to stress using LV OS-CMR in SSc patients without known cardiac disease. Methods: We prospectively recruited SSc patients without prior cardiac disease or risk factors, and age- and sex-matched healthy volunteers (HVs). All participants underwent transthoracic echocardiography (TTE) and 3T CMR, including native T1 mapping, rest/stress OS-CMR, stress perfusion, and late gadolinium enhancement (LGE). The primary outcome was a change in the LV OS-CMR signal intensity (SI) after adenosine stress. Results: Thirty-three participants (23 SSc, 10 HV) were enrolled. SSc patients had significantly lower global LV OS-CMR SI compared to HV (13.4 ± 6.5 vs. 19.5 ± 3.6, p = 0.011). OS-CMR SI change ≤ 10% was observed in at least one segment in 20 (87%) SSc patients and globally in 12 (52%). LGE was present in 5 (22%) patients, and 18 (78%) had ≥1 abnormal T1 mapping segment. LV global longitudinal strain (GLS) was reduced in SSc patients compared to the HVs (−19.04 ± 3.86 vs. −21.92 ± 3.72, p = 0.045). All HVs had normal CMR and TTE findings. Conclusions: SSc patients without known cardiovascular disease or PAH demonstrated subclinical LV ischemia with an impaired myocardial oxygenation response to stress. They further demonstrated LV myocardial deformation abnormalities and LV diffuse fibrosis when compared to an age-matched control group. Our findings support the presence of early coronary microvascular dysfunction and LV myocardial fibrosis in this population, which may explain the adverse cardiovascular risk seen in this population, independent of the presence of PAH.


  • Myocardial Injury Following Immune Checkpoint Inhibitors: An Australian Experience

    by Briella K. Egberts, Rajiv Ananthakrishna, Rebecca Perry, Richard J. Woodman, Alison Sutton, Sivabaskari Pasupathy, Teresa Hecker, Tonia A. Bromley, Woo Sze Yang, Christos Karapetis, et al.


  • Utility of cardiovascular magnetic resonance in patients with stable troponin elevation

    by Rajiv Ananthakrishna, Benita P Rajvi, Diana E Hancock, Feruza Kholmurodova, Richard J Woodman, Sanjana Patil, Matthew Horsfall, Derek P Chew, Noor Darinah Mohd Daril, Joseph B Selvanayagam

    Aims: Cardiovascular magnetic resonance (CMR) imaging has a potential role in the evaluation of symptomatic patients with stable troponin elevation; however, its utility remains unexplored. We sought to determine the incremental diagnostic value of CMR in this unique cohort and assess the long-term clinical outcomes. Methods and results: Two hundred twenty-five consecutive patients presenting with cardiac chest pain/dyspnoea, stable troponin elevation, and undergoing CMR assessment were identified retrospectively from registry database. The study cohort was prospectively followed for major adverse cardiac events (MACEs) (defined as composite of all-cause mortality and cardiovascular readmissions). The primary outcome measure was the diagnostic utility of CMR, i.e. percentage of patients for whom CMR identified the cause of stable troponin elevation. Secondary outcome measures included the incremental value of CMR and occurrence of MACE. CMR was able to identify the cause for stable troponin elevation in 160 (71%) patients. A normal CMR was identified in 17% and an inconclusive CMR in 12% of the patients. CMR changed the referral diagnosis in 59 (26%) patients. Utilizing a baseline prediction model (pre-CMR referral diagnosis), the net reclassification index was 0.11 and integrated discriminatory improvement index measured 0.33 following CMR. Over a median follow-up of 4.3 years (interquartile range 2.8–6.3), 72 (32%) patients experienced MACE. Conclusion: CMR identified a cause for stable troponin elevation in 7 of 10 cases, and a new diagnosis was evident in 1 of 4 cases. CMR improved the net reclassification of patients with stable troponin elevation.


  • Myocardial Oxygenation in Hibernating Myocardium

    by Rajiv Ananthakrishna, Karthigesh Sree Raman, Ranjit Shah, Richard J. Woodman, Angela Walls, Craig Bradbrook, Suchi Grover, Joseph B. Selvanayagam


  • Open Access

    “Incidence, clinical and angiographic characteristics, management and outcomes of coronary artery perforation at a high volume cardiac care center during percutaneous coronary intervention”

    by Chetana Krishnegowda, Beeresha Puttegowda, Santhosh Krishnappa, Rajiv Ananthakrishna, Nagesh C. Mahadevappa, Sadananda K. Siddegowda, Raghu T. Ramegowda, Cholenahally N. Manjunath


  • Open Access

    Cardiac Amyloidosis

    by Rajiv Ananthakrishna, Rachael Lloyd, Bryone J. Kuss, Joseph B. Selvanayagam


  • Open Access

    Chronic postrheumatic fever arthropathy

    by Nagaraja Moorthy, Rajiv Ananthakrishna

    Cite this article as: Moorthy N, Ananthakrishna R. Chronic postrheumatic fever arthropathy. Eur J Rheumatol 2019; 6(3): 163-4.

  • Intracardiac mass in chronic myeloid leukemia

    by Chetana Krishnegowda, Srinivas Budanur Chikkaswamy, Ashita Barthur, Rajiv Ananthakrishna

    Chronic myeloid leukaemia (CML) is a neoplastic disorder of myeloid cell lines and is a less aggressive disease compared to acute myeloid leukemia (AML). Although cardiovascular complications are not uncommon, intracardiac thrombosis in CML is rarely reported. Herein, we report a case of CML presenting with an intracardiac thrombus attached to the posterior mitral leaflet, and subsequently resulting in peripheral embolization.


    • 1 July 2018
      • Vol. 30  (7) , 256-261

    Treatment of Very Small De Novo Coronary Artery Disease With 2.0 mm Drug-Coated Balloons Showed 1-Year Clinical Outcome Comparable With 2.0 mm Drug-Eluting Stents

    by Hui Wen Sim, Rajiv Ananthakrishna, Siew Pang Chan, Adrian F. Low, Chi-Hang Lee, Mark Y. Chan, Edgar L. Tay, Poay Huan Loh, Koo Hui Chan, Huay Cheem Tan, et al.

    Objective. To evaluate the 1-year clinical outcomes of patients treated with 2.0 mm drug-coated balloon (DCB) vs 2.0 mm drug-eluting stent (DES) implantation in small-caliber vessel de novo coronary artery disease (CAD). Methods. All patients treated with 2.0 mm DCB or 2.0 mm DES for very small vessel de novo CAD from July 2014 to June 2016 were included in this study. The primary endpoint was the occurrence of target-lesion failure (TLF) and time to TLF, defined as a combination of cardiac mortality, target-vessel myocardial infarction, and target-lesion revascularization (TLR). Results. A total of 87 patients (96 lesions) were implanted with 2.0 mm DCBs and 200 patients (223 lesions) were implanted with 2.0 mm DESs during the study period. Mean reference vessel diameter was similar between the DCB and DES groups (1.88 +/- 0.38 mm vs 1.95 +/- 0.21 mm, respectively; P=.11). The 1-year TLF rates were 7.0% in the DCB group and 8.2% in the DES group (P=.73). TLF was driven by TLR in both groups. Bailout stenting was performed in 7 patients (8 lesions) who received a DCB. Stent thrombosis was seen in 4 patients (2.0%) who underwent DES implantation. There was no vessel thrombosis noted in the DCB group. Cardiogenic shock was identified as a direct and significant predictor for both the occurrence of TLF and time to TLF. Conclusions. In this first report, treatment of very small vessel CAD with 2.0 mm DCB vs 2.0 mm DES was associated with similar 1-year TLF rates.